Versor Investments LP Invests $263,000 in Solventum Co. (NYSE:SOLV)

Versor Investments LP bought a new stake in Solventum Co. (NYSE:SOLV) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,976 shares of the company’s stock, valued at approximately $263,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SOLV. Trian Fund Management L.P. boosted its holdings in Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after purchasing an additional 1,765,676 shares in the last quarter. State Street Corp raised its holdings in shares of Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after buying an additional 185,938 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after buying an additional 128,317 shares during the period. Hotchkis & Wiley Capital Management LLC acquired a new stake in Solventum in the 3rd quarter valued at $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Solventum by 0.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after acquiring an additional 3,745 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SOLV. Wells Fargo & Company lifted their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday. Bank of America lifted their price target on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. The Goldman Sachs Group upped their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday. Morgan Stanley lifted their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, Piper Sandler increased their price target on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $78.86.

Solventum Price Performance

SOLV opened at $80.07 on Tuesday. The company’s 50 day simple moving average is $72.78 and its 200-day simple moving average is $70.20. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a market capitalization of $13.83 billion and a P/E ratio of 29.12.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.